company background image
ARUX.F logo

Acrux OTCPK:ARUX.F Stock Report

Last Price

US$0.03

Market Cap

US$8.0m

7D

0%

1Y

n/a

Updated

02 Feb, 2025

Data

Company Financials +

ARUX.F Stock Overview

Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. More details

ARUX.F fundamental analysis
Snowflake Score
Valuation4/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Acrux Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Acrux
Historical stock prices
Current Share PriceAU$0.03
52 Week HighAU$0.055
52 Week LowAU$0.021
Beta1.22
1 Month Change0%
3 Month Change41.59%
1 Year Changen/a
3 Year Change-46.65%
5 Year Change-72.45%
Change since IPO-96.91%

Recent News & Updates

Recent updates

Shareholder Returns

ARUX.FUS PharmaceuticalsUS Market
7D0%2.4%-0.8%
1Yn/a4.3%22.7%

Return vs Industry: Insufficient data to determine how ARUX.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ARUX.F performed against the US Market.

Price Volatility

Is ARUX.F's price volatile compared to industry and market?
ARUX.F volatility
ARUX.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.3%
Market Average Movement6.4%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: ARUX.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ARUX.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998n/aMichael Kotsaniswww.acrux.com.au

Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores.

Acrux Limited Fundamentals Summary

How do Acrux's earnings and revenue compare to its market cap?
ARUX.F fundamental statistics
Market capUS$8.00m
Earnings (TTM)-US$3.60m
Revenue (TTM)US$3.16m

2.5x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARUX.F income statement (TTM)
RevenueAU$5.09m
Cost of RevenueAU$6.38m
Gross Profit-AU$1.28m
Other ExpensesAU$4.52m
Earnings-AU$5.80m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.014
Gross Margin-25.22%
Net Profit Margin-113.93%
Debt/Equity Ratio45.4%

How did ARUX.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 01:15
End of Day Share Price 2024/11/06 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acrux Limited is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
John HesterBell Potter
Matthijs SmithCanaccord Genuity